Willingness to participate in preventive HIV vaccine trials in a community-based cohort in South Western Uganda

Simple item page
dc.contributor.authorRuzagira, Eugene
dc.contributor.authorWandiembe, Symon
dc.contributor.authorBufumbo, Leonard
dc.contributor.authorLevin, Jonathan
dc.contributor.authorPrice, Matthew A.
dc.contributor.authorGrosskurth, Heiner
dc.contributor.authorKamali, Anatoli
dc.date.accessioned2022-01-20T08:37:27Z
dc.date.available2022-01-20T08:37:27Z
dc.date.issued2009
dc.description.abstractTo assess willingness to participate in HIV vaccine trials and possible barriers to participation. methods Questionnaire survey of participants completing a 2-year community-based HIV Vaccine Preparedness Study, followed by cross sectional analysis of data. results 95% of participants were willing to participate in a trial with similar attributes to the Vaccine Preparedness Study. Certain hypothetical trial attributes significantly reduced willingness to participate: The requirement to delay pregnancy (for females) had the largest effect, reducing willingness to participate from 97% to 23% (P < 0.0001). Larger blood draws had the second largest effect: 95–55% (P < 0.0001). The possibility of receiving either candidate vaccine or placebo had the third largest effect: 95–73% (P < 0.0001). Monthly study visits had the fourth largest effect: 95–92% (P < 0.0001). Trial duration longer than 2 years had the least effect: 95–93% (P = 0.0025). Combined attributes reduced willingness to participate from 95% to 43% (McNemar’s v2 = 521.00; P < 0.0001) overall and 97–11% (McNemar’s v2 = 531.00; P < 0.0001) for female participants. Physical harm concerns (adjusted OR = 34.9; 95% CI, 10.4–118) and a low risk behaviour index (adjusted OR = 0.09; 95% CI, 0.01–0.73) were associated with unwillingness to participate. conclusions We found a high level of willingness to participate in HIV vaccine trials in this population. However, certain HIV vaccine trial requirements were associated with reduced willingness to participate. Community as well as individual concerns will have to be carefully addressed in planned HIV vaccine trials.en_US
dc.identifier.citationRuzagira, E., Wandiembe, S., Bufumbo, L., Levin, J., Price, M. A., Grosskurth, H., & Kamali, A. (2009). Willingness to participate in preventive HIV vaccine trials in a community‐based cohort in south western Uganda. Tropical medicine & international health, 14(2), 196-203. doi:10.1111/j.1365-3156.2008.02200.xen_US
dc.identifier.other10.1111/j.1365-3156.2008.02200.x
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1334
dc.language.isoenen_US
dc.publisherTropical medicine & international healthen_US
dc.subjectHIV vaccine trialen_US
dc.subjectWillingnessen_US
dc.subjectCommunity-baseden_US
dc.subjectBarriersen_US
dc.titleWillingness to participate in preventive HIV vaccine trials in a community-based cohort in South Western Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Tropical Med Int Health - 2009 - Ruzagira - Willingness to participate in preventive HIV vaccine trials in a.pdf
Size:
62.54 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences